Apitope MS Vaccine Shows Promise
Apitope Technology Ltd. (Bristol, UK), has announced the completion of dosing for all six multiple sclerosis (MS) patients in a Phase 1/2a trial of ATX-MS-1467
Apitope Technology Ltd. (Bristol, UK), has announced the completion of dosing for all six multiple sclerosis (MS) patients in a Phase 1/2a trial of ATX-MS-1467. The therapeutic vaccine was found to be safe and well tolerated in secondary progressive multiple sclerosis (SPMS) patients.
Although efficacy was not an endpoint of this trial, one patient, with optic neuritis resulting from the neuroinflammatory process involved in MS, did demonstrate a clinically significant improvement in visual acuity post treatment. This was demonstrated in analysis of the initial visual acuity examination at screening compared to the one-month follow up test.
The ATX-MS-1467 Phase 1/2a open label trial was designed as a dose-escalation study to assess the safety and tolerability with all six patients receiving five escalating doses given seven to 14 days apart of 25, 50, 100, 400, and 800 µg followed by a repeat of the 800 µg dose.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
